X

Use of cookies
This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, as well as to change their configuration, see our Cookie Policy.

Non-invasive prenatal test Nace
teléfono +34 96 3905310

Non-invasive prenatal test Nace

Medical professionals

Why a non-invasive prenatal test?

Non-invasive prenatal tests can prevent the need for about 98% of invasive tests in patients at risk for T211.

* The current standard for detecting prenatal chromosomal alterations requires
the use of invasive techniques (amniocentesis and chorionic villus biopsy), which carry a risk between 0.5%-2% of spontaneous abortion.

* NACE® provides reliable information which avoids the need for unnecessary invasive techniques.

Coverage of the NACE® test for single pregnancies ordered by their importance

Coverage of the NACE® test for single pregnancies ordered by their importance

According to data from the 2012 European Registry for Prenatal Diagnosis2, abnormalities
in chromosomes 21, 18, and 13 represent 71% of all chromosomal alterations detected.

Detection rate according to the type of screening

Type of screening

NACE®2

1sttrimester
combined screening*

Extended combined screening**

Gestational age

From week 10
9-13 weeks
11-13 weeks

Detection rate

99,92% (FP<0.1%)
T21/T18/T13
80-85% (FP 5%)
85-93% (FP 2.5%)

Microdeletions

Microdeletions are chromosomal diseases caused by small losses in chromosomal material. The majority occur by chance, without a family history or other risk factors such as advanced age. These syndromes are generally associated with intellectual disability and malformation of dierent organs.

The NACE® Extended 24 panel of microdeletions provides physicians with a new option for a non-invasive assay/test in certain clinical situations.

The NACE® Extended 24 panel of microdeletions has been validated with clinical samples and real analyses. Its optimized algorithm deals with the complexities of these specific chromosomal regions to provide accurate answers about the loss of genetic material. The result is overall better performance, including a low false-positive rate in comparison with other tests and the lowest failure rate in the sector for this type of assay.3

Efficacy of the assay/test and its exact reliability and accuracy

Overall sensitivity of 91.6% and precision of 99.84%
NACE test efficacy

subir
Logo Igenomix para el calendario chino bebé

Pin It on Pinterest